Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ayse Altintas

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 16, 2021
Retinal Optical Coherence Tomography in Neuromyelitis OpticaFrederike Cosima Oertel, Svenja Specovius, Hanna G Zimmermann, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
BMJ Open|October 30, 2020
Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO)Svenja Specovius, Hanna G Zimmermann, Frederike Cosima Oertel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2021
Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disordersAngelo Lu, Hanna G Zimmermann, Svenja Specovius, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Neurology(R) Neuroimmunology & Neuroinflammation|October 23, 2024
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying TherapiesWei Z Yeh, Anneke Van Der Walt, Olga G Skibina, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|September 16, 2021
Retinal Optical Coherence Tomography in Neuromyelitis OpticaFrederike Cosima Oertel, Svenja Specovius, Hanna G Zimmermann, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 18, 2025
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosisSimona Toscano, Tim Spelman, Serkan Ozakbas, et al.
Journal of Neurology|June 27, 2024
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemicAnoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, et al.
Journal of Neurology|September 28, 2023
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategiesYing Li, Alice Saul, Bruce Taylor, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 6, 2023
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trialIbrahima Diouf, Charles B Malpas, Sifat Sharmin, et al.
BMJ Open|October 30, 2020
Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO)Svenja Specovius, Hanna G Zimmermann, Frederike Cosima Oertel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 10, 2019
Risk of secondary progressive multiple sclerosis: A longitudinal studyAdam Fambiatos, Vilija Jokubaitis, Dana Horakova, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 29, 2021
Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disordersAngelo Lu, Hanna G Zimmermann, Svenja Specovius, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 17, 2023
Disability accrual in primary and secondary progressive multiple sclerosisSam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, et al.
Pageof 9